Figure 3 (panel hepatitis) shows that serum levels of CTACK during treatment are negatively correlated with hepatitis (ME -0.23, SD 0.04). Figure 3 also indicates that during treatment, an increase in TNF-α is associated with concurrent hepatitis (ME 0.35, SD 0.04). The gene discussed is CCL27; the disease is hepatitis A virus infection.